GoodRx Stock Jumps 37% On Novo Nordisk Collaboration

(RTTNews) - GoodRx Holdings, Inc. (GDRX) surged 37.00 percent to $5.11, up $1.38 on Monday, after announcing a collaboration with Novo Nordisk that makes all strengths of Ozempic and Wegovy pens available to eligible self-paying patients for $499 per month through its platform. The stock opened at $4.64 and traded between $4.48 and $5.41, with volume spiking to 49.23 million shares compared to an average of 1.50 million on the Nasdaq. GoodRx has a 52-week range of $3.31 to $8.80.

The move marks the first time Ozempic has been offered at this self-pay price and expands access to two of the nation's most in-demand GLP-1 medications for patients without adequate insurance coverage.